<DOC>
	<DOCNO>NCT02649972</DOCNO>
	<brief_summary>The purpose study find effect , good bad , Cobimetinib patient histiocytosis . Cobimetinib investigational oral medication block MEK1 .</brief_summary>
	<brief_title>Single-agent Cobimetinib Adults With Histiocytic Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<criteria>Histologically confirm histiocytic disorder histologic finding compatible histiocytic disorder context confirmatory radiologic finding One following : Documentation BRAF V600E mutation inability access BRAF inhibitor prior treatment BRAF inhibitor discontinue due intolerable side effect toxicity prior progression , OR Documentation wildtype BRAF V600 mutational status Measurable disease accord PET Response Criteria , exception patient cutaneous disease measure followed RECIST criterion Histiocytic disorder must ( ) multisystem disease ( b ) disease recurrent refractory standard therapy , ( c ) singlesystem disease unlikely benefit conventional less toxic therapy , base best available evidence ( example , CNS cardiac infiltration , retroperitoneal fibrosis , prior chemotherapy , medical history comorbidities , etc ) Life expectancy &gt; 12 week Age ≥ 16 year ECOG performance status ≤ 3 Adequate bone marrow function indicate follow : ANC &gt; 1000/uL Platelets ≥ 50,000/uL Hemoglobin ≥ 8.5 g/dL . Patients cytopenias threshold deem result disease consider eligible . Adequate renal function , indicate : creatinine ≤ 1.5 upper limit normal ( ULN ) OR Estimated creatinine clearance &gt; 50 ml/min As # 7 , patient renal dysfunction deem result disease consider eligible . Adequate liver function , define bilirubin ≤ 1.5 ULN AND AST/ALT &lt; 3 ULN Ability swallow pill Negative serum pregnancy test within 7 day prior commencement dose premenopausal woman . Women nonchildbearing potential may include without serum pregnancy test either surgically sterile postmenopausal ≥ 1 year . Fertile men woman must use effective method contraception treatment least 6 month completion treatment direct physician . Effective method contraception define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly ( example implant , injectables , combine oral contraception intrauterine device ) . At discretion Investigator , acceptable method contraception may include total abstinence case lifestyle patient ensures compliance . ( Periodic abstinence [ e.g. , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Patients must willing consent protocol # 12245 IMPACT test . To date , patient BRAFmutated ECD/LCH disease progression BRAF inhibitor therapy . Such patient would eligible would require tissue biopsy genotyping participate . Prior treatment MEK inhibitor Active infection require intravenous antibiotic Pregnant , lactate breast feeding woman Prior radiation therapy within last 14 day Unwillingness inability comply study followup procedure . Any foods/supplements strong inhibitor inducer CYP3A CYP2D6 prohibit least 7 day prior initiation study treatment History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment , RVO , neovascular macular degeneration The risk factor RVO list . Exclusion consider clinical discretion follow condition : Uncontrolled glaucoma intraocular pressure &gt; 21mmHg Serum cholesterol ≥ Grade 2 Hypertriglyceridemia ≥ Grade 2 Hyperglycemia ≥ Grade 2 History clinically significant cardiac dysfunction , unless deem direct result disease , include follow : Current unstable angina Symptomatic congestive heart failure NYHA class 2 high Uncontrolled hypertension ≥ Grade 2 ( patient history hypertension control antihypertensive ≤ Grade 1 eligible ) . Left ventricular ejection fraction ( LVEF ) institutional low limit normal 50 % Uncontrolled Arrhythmias Myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack within previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cobimetinib</keyword>
	<keyword>15-216</keyword>
</DOC>